
NASH Market Shifts Toward Fibrosis-Confirmed Treatment Pathways
The global market for metabolic dysfunction-associated steatohepatitis (MASH) is entering a period of rapid expansion, with valuations projected to climb from USD 8.75 billion in 2025 to USD 46.87 billion by 2032. Growth is currently driven by the establishment of formal prescription pathways for patients with moderate-to-advanced liver fibrosis.






















